Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

@article{Kollmannsberger2002IrinotecanIP,
  title={Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group},
  author={Christian K. Kollmannsberger and Oliver Rick and H. Klaproth and T Kubin and Herbert Gottfried Sayer and M Hentrich and M Welslau and F Mayer and Markus Antonius Kuczyk and C Spott and L Kanz and C Carsten Bokemeyer},
  journal={British Journal of Cancer},
  year={2002},
  volume={87},
  pages={729 - 732}
}
Despite generally high cure rates in patients with metastatic germ cell cancer, patients with progressive disease on first-line cisplatin-based chemotherapy or with relapsed disease following high-dose salvage therapy exhibit a very poor prognosis. Irinotecan has shown antitumour activity in human testicular tumour xenografts in nude mice. We have performed a phase II study examining the single agent activity of irinotecan in patients with metastatic relapsed or cisplatin-refractory germ cell… CONTINUE READING